{"id":"cd52","name":"CD52","symbol":"CD52","route":"/targets/cd52/","asOf":"2026-09-08","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1804","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169442","uniprot":"https://www.uniprot.org/uniprotkb/P31358/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P31358","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1912","open-targets":"https://platform.opentargets.org/target/ENSG00000169442","civic":"https://civicdb.org/genes/1043/summary","oncokb":"https://www.oncokb.org/gene/CD52","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD52","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CD52","depmap":"https://depmap.org/portal/gene/CD52?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000169442-CD52","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1043","omim":"https://www.omim.org/entry/114280"}],"products":[{"id":"alemtuzumab","name":"Alemtuzumab","status":"approved","modality":"Monoclonal antibody (anti-CD52)","route":"/drugs/alemtuzumab/"},{"id":"allo-647","name":"ALLO-647","status":"phase-2","modality":"monoclonal antibody","route":"/drugs/allo-647/"}],"trials":[{"id":"nct04416984","name":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","nct":"NCT04416984","phase":"1/2","status":"active"},{"id":"nct05607420","name":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","nct":"NCT05607420","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["allogene","sanofi"],"keyPapers":["paper-hillmen-j-clin-oncol"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}